FY2027 Earnings Forecast for LXRX Issued By HC Wainwright

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) – Stock analysts at HC Wainwright issued their FY2027 EPS estimates for Lexicon Pharmaceuticals in a research report issued on Thursday, March 5th. HC Wainwright analyst J. Pantginis expects that the biopharmaceutical company will earn ($0.21) per share for the year. HC Wainwright currently has a “Buy” rating and a $6.00 price objective on the stock. The consensus estimate for Lexicon Pharmaceuticals’ current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for Lexicon Pharmaceuticals’ FY2028 earnings at ($0.18) EPS.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its earnings results on Thursday, March 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 96.77% and a negative return on equity of 52.90%. The company had revenue of $5.49 million during the quarter, compared to analysts’ expectations of $3.14 million.

LXRX has been the topic of several other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, November 15th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $4.63.

Lexicon Pharmaceuticals Stock Performance

Shares of LXRX opened at $1.64 on Friday. The company has a current ratio of 5.64, a quick ratio of 5.63 and a debt-to-equity ratio of 0.47. The firm has a market cap of $596.09 million, a PE ratio of -8.63 and a beta of 0.94. Lexicon Pharmaceuticals has a 12 month low of $0.32 and a 12 month high of $1.83. The stock has a fifty day moving average price of $1.35 and a 200-day moving average price of $1.33.

Insider Buying and Selling at Lexicon Pharmaceuticals

In related news, Director Invus Global Management, Llc bought 1,538,462 shares of the stock in a transaction dated Monday, February 2nd. The shares were purchased at an average price of $1.30 per share, for a total transaction of $2,000,000.60. Following the completion of the purchase, the director directly owned 1,538,462 shares of the company’s stock, valued at $2,000,000.60. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Raymond Debbane bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, February 23rd. The shares were bought at an average cost of $1.47 per share, for a total transaction of $147,000.00. Following the completion of the acquisition, the director owned 1,904,186 shares of the company’s stock, valued at $2,799,153.42. This trade represents a 5.54% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders acquired 1,790,462 shares of company stock worth $2,369,981. 13.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Lexicon Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in LXRX. Vanguard Group Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 7.6% in the 3rd quarter. Vanguard Group Inc. now owns 9,521,874 shares of the biopharmaceutical company’s stock valued at $12,855,000 after purchasing an additional 670,838 shares during the period. Millennium Management LLC raised its position in shares of Lexicon Pharmaceuticals by 25.9% in the fourth quarter. Millennium Management LLC now owns 4,821,733 shares of the biopharmaceutical company’s stock worth $5,545,000 after acquiring an additional 991,073 shares during the period. UBS Group AG raised its position in shares of Lexicon Pharmaceuticals by 752.1% in the fourth quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock worth $3,458,000 after acquiring an additional 2,654,315 shares during the period. Geode Capital Management LLC boosted its stake in shares of Lexicon Pharmaceuticals by 4.3% during the 4th quarter. Geode Capital Management LLC now owns 2,500,022 shares of the biopharmaceutical company’s stock worth $2,876,000 after acquiring an additional 102,099 shares in the last quarter. Finally, CIBC Bancorp USA Inc. acquired a new stake in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at about $3,240,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Key Headlines Impacting Lexicon Pharmaceuticals

Here are the key news stories impacting Lexicon Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $6.00 and reiterated a Buy, signaling strong analyst conviction and large implied upside versus the current price. Higher analyst targets can attract buyers and support momentum. Street Insider: PT Raised to $6
• Positive Sentiment: Q4 results beat estimates: GAAP EPS of -$0.04 beat consensus and revenue of $5.49M topped forecasts, which reduces near‑term execution risk and supports the narrative of improving fundamentals. Earnings Beat
• Positive Sentiment: Clinical and corporate milestones announced: planned NDA resubmission for sotagliflozin in T1D, SONATA enrollment for HCM, positive End‑of‑Phase‑2 meeting for pilavapadin (supporting Phase 3 readiness), and ongoing partnership talks — all de‑risk future value catalysts. Press Release: Q4 Results & Clinical Updates
• Positive Sentiment: Balance sheet strengthened: management disclosed more than $100M in additional cash from a capital raise and a Novo Nordisk milestone payment, improving runway and reducing near‑term financing risk. Press Release: Cash Update
• Neutral Sentiment: Management commentary and full Q4 call transcript available for investors to assess execution details and timelines. Review the transcript/webcast for guidance nuances. Earnings Call Transcript
• Neutral Sentiment: Analyst model updates: HC Wainwright published FY2027/FY2028 EPS forecasts (-$0.21 and -$0.18) that are better than the current consensus (-$0.66 for the year), reflecting expectations of narrowing losses but still negative near‑term earnings. Analyst Estimates
• Negative Sentiment: Company remains unprofitable with a negative net margin (~96.8%) and negative ROE; earnings are expected to remain below zero in the near term—a structural risk that keeps the stock speculative. Earnings Detail

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.